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Abstract
Essential hypertension (HT) is associated with endothelial dysfunction augmented vasoconstriction (VC) which may be 
secondary to increased Rho/Rho-Kinase (ROCK)-dependent mechanisms. Our aim was to assess the in vivo magnitude 
of cutaneous VC to local cooling as a ROCK specific stimulus, and in vitro evaluate ROCK activity in skin from HT 
humans. Four microdialysis fibers were placed in the forearm of 9 pre- to stage I hypertensive (MAP: 106 ± 3 mmHg) 
and 11 normotensive (NT; 86 ± 1 mmHg) men and women: Ringers (control), 3 mM fasudil (ROCK inhibited), 5 mM 
yohimbine + 1 mM proprananol (α- and β-adrenoceptor inhibited; Y + P), Y + P + 3 mM fasudil (ROCK and 
adrenocepor inhibited). Skin blood flow was measured during local cooling (Tskl 24°C) and ROCK activity in skin 
biopsy samples was determined with western blot. In vitro phosphorylated myosin phosphatase target subunit 1
(pMYPT-1)/ROCK was increased in HT skin samples (p=0.0018). Functionally, no difference in basal vasomotor tone 
(Tskl 34°C) was observed between groups (HT: 0.36 ± 0.07 vs. NT: 0.31 ± 0.07 CVC), nor at the control site during local 
cooling. Pre- to stage 1 hypertensives show greater ROCK-mediated vasoconstriction at early (1–5 min; HT: −0.8±0.2 
versus NT: −0.3±0.2 ΔCVC baseline 1; P<0.0001) and late (36–40 min; HT: −0.9±0.1 versus NT: −0.5±0.2 ΔCVC 
baseline 1; P<0.0001) phases of local cooling. These data suggest that the magnitude of cutaneous vasoconstriction to 
local cooling does not differ in normotensive and pre- to stage I essential hypertensive humans; however, ROCK 
activity is increased and functional vasoconstriction is increasingly dependent upon Rho/ROCK mechanisms with 
essential hypertension.
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Abstract 
Essential hypertension (HT) is associated with endothelial dysfunction augmented 
vasoconstriction (VC) which may be secondary to increased Rho/Rho-Kinase (ROCK)-dependent 
mechanisms. Our aim was to assess the in vivo magnitude of cutaneous VC to local cooling as a 
ROCK specific stimulus, and in vitro evaluate ROCK activity in skin from HT humans. Four 
microdialysis fibers were placed in the forearm of 9 pre- to stage I hypertensive (MAP: 106 ± 3 
mmHg) and 11 normotensive (NT; 86 ± 1 mmHg) men and women: Ringers (control), 3 mM 
fasudil (ROCK inhibited), 5 mM yohimbine + 1 mM proprananol (α- and β-adrenoceptor 
inhibited; Y + P), Y + P + 3 mM fasudil (ROCK and adrenocepor inhibited). Skin blood flow was 
measured during local cooling (Tskl 24°C) and ROCK activity in skin biopsy samples was 
determined with western blot. In vitro phosphorylated myosin phosphatase target subunit 1 
(pMYPT-1)/ROCK was increased in HT skin samples (p=0.0018). Functionally, no difference in 
basal vasomotor tone (Tskl 34°C) was observed between groups (HT: 0.36 ± 0.07 vs. NT: 0.31 ± 
0.07 CVC), nor at the control site during local cooling. Pre- to stage 1 hypertensives show greater 
ROCK-mediated vasoconstriction at early (1–5 min; HT: −0.8±0.2 versus NT: −0.3±0.2 ΔCVC 
baseline 1; P<0.0001) and late (36–40 min; HT: −0.9±0.1 versus NT: −0.5±0.2 ΔCVC baseline 1; 
P<0.0001) phases of local cooling. These data suggest that the magnitude of cutaneous 
vasoconstriction to local cooling does not differ in normotensive and pre- to stage I essential 
hypertensive humans; however, ROCK activity is increased and functional vasoconstriction is 
increasingly dependent upon Rho/ROCK mechanisms with essential hypertension. 
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Introduction 
Abnormal RhoA/Rho Kinase (ROCK) signaling in vascular smooth muscle cells (VSMC) 
has been implicated in the pathogenesis of cardiovascular disease. In hypertensive animal 
models ROCK activity is upregulated and contributes to endothelial dysfunction, and 
vascular remodeling. The pathogenesis of hypertension is multifaceted, involving 
inflammation, endothelial dysfunction, and upregulation of pro-constrictor pathways. 
Microvascular dysfunction is evident in essential hypertensive humans (Holowatz and 
Kenney, 2007c; Serne et al., 2001; Smith et al., 2011) and evolves in parallel in multiple 
vascular beds (Abularrage et al., 2005; Coulon et al., 2011). In concert with endothelial 
dysfunction altered ROCK-dependent vasoconstriction (VC) in the cutaneous circulation 
may precede impairments in conduit vessel function (Cohuet and Struijker-Boudier, 2006; 
Holowatz and Kenney, 2007a; Holowatz and Kenney, 2007c; Lauer et al., 2005; Levy et al., 
2001; Rizzoni and Agabiti-Rosei, 2001; Rizzoni et al., 2003), making the skin a minimally 
invasive, easily accessible, generalizable vascular bed for assessing in vivo vascular function 
and dysfunction in pre-clinical and cardiovascular disease groups (Abularrage et al., 2005; 
Holowatz et al., 2008; Rossi et al., 2006; Stewart et al., 2004). 
Accumulating evidence supports the involvement of ROCK in hypertension, yet its role in 
cutaneous microvascular dysfunction has not been elucidated in a hypertensive human 
model. Animal and in vitro studies have demonstrated the upregulation of ROCK by 
inflammatory stimuli, including superoxide anion (O2˙−), acting to increase VSMC 
contractility via two mechanisms including: 1) a Ca2+ independent increase in the 
translocation of α2c-adrenoceptors from the Golgi apparatus to the plasma membrane, and 
2) inhibition of myosin light chain phosphatase (MLCP) increasing intracellular Ca2+
sensitivity (Bailey et al., 2004; Chotani et al., 2000; Jeyaraj et al., 2001). Furthermore, 
ROCK negatively regulates the nitric oxide (NO) pathway via inhibition of endothelial nitric 
oxide synthase (eNOS) gene expression, eNOS activation, and NOS uncoupling resulting 
from O2˙− production (Eto et al., 2001; Ming et al., 2002; Takemoto et al., 2002). Further 
increases in O2˙− production from uncoupled eNOS and other hypertension-associated 
elevations in the activity of enzymes NAD(P)H oxidase and xanthine oxidase (Feletou et al., 
2009; Tang and Vanhoutte, 2008) lead to a relative vasoconstriction. 
Our laboratory has previously demonstrated that locally-mediated VC becomes less 
adrenergic and more ROCK dependent with advancing age (Thompson-Torgerson et al., 
2007b), reflecting a compensatory pathway to preserve the VC response and highlighting the 
shift towards a ‘pre-clinical’ pro-constrictor vascular state. More recently, we reported an 
attenuation of cutaneous eNOS-derived NO-dependent vasodilation in essential hypertensive 
human skin (Smith et al., 2011), consistent with the ROCK-dependent downregulation of the 
NO pathway. The purpose of the present study was to examine the role of Rho-Kinase in 
pre- to stage 1 hypertension-induced cutaneous microvascular dysfunction, using the 
ROCK-specific stimulus of local skin cooling (Bailey et al., 2004; Thompson-Torgerson et 
al., 2007a). We hypothesized that in vivo augmented cutaneous VC in pre- to early stage 
essential hypertensive humans results from upregulation of Rho-Kinase during local cooling 
compared to normotensive age-matched controls. We further hypothesized that in vitro Rho- 
  
 
Kinase expression and activity would be increased in skin samples obtained from pre- to 
stage 1 essential hypertensive humans. 
 
Materials and Methods 
Subjects 
Experimental protocols were approved by the Institutional Review Board at The 
Pennsylvania State University and conformed to the guidelines set forth by the Declaration 
of Helsinki. Verbal and written consent were voluntarily obtained from all subjects prior to 
participation. Nine unmedicated pre- to stage 1 essential hypertensive (50 ± 1 years, 5 men 
and 4 women) and eleven normotensive age-matched control subjects (51 ± 1 years, 3 men 
and 8 women) participated in the study. Each subject reported to the laboratory on three 
separate occasions to determine their blood pressure status in accordance with the guidelines 
set forth by the American Heart Association (AHA, 2006). Hypertensive status was further 
assessed using a 24 hour ambulatory blood pressure monitor to obtain values every hour 
over a 24 hour period (Ambulo 2400, Tiba Medical, Portland OR, USA). Subject 
classification in the pre- to stage 1 hypertension group was assessed based on American 
Heart Association guidelines for abnormal ambulatory pressure defined as a sustained 
pressure greater than 130 mmHg systolic and 80 mmHg diastolic values (Izzo et al., 2008; 
Pickering et al., 2005). Subjects underwent a complete medical screening, including blood 
chemistry, complete lipid, renal, and liver enzyme profile evaluation (Quest Diagnostics 
Nichol Institute, Chantilly, VA), resting electrocardiogram, and physical examination. All 
subjects were screened for the presence of cardiovascular, dermatological, and neurological 
disease. Subjects were nonobese, nonsmokers, nondiabetic, normally active (neither 
sedentary nor highly exercise trained), and were not taking medications including 
antihypertensives or other drugs that may affect the cardiovascular system, including 
antioxidants, hormone replacement therapy, or oral contraceptives. Eight out of the nine pre- 
to stage 1 essential hypertensive subjects had never taken antihypertensive pharmacotherapy 
and one subject had previously been on antihypertensive drugs but had not taken them for 
over a year. All women were postmenopausal except three normotensive females. 
 
In Vivo Vasoreactive Studies 
Protocols were performed in a thermoneutral laboratory with the subject semi-supine and the 
experimental arm at heart level (Figure 1). Four intradermal microdialysis fibers (MD 2000, 
Bioanalytical Systems) (10 mm, 20-kDa cutoff membrane) were inserted into the left ventral 
forearm skin as previously described (Holowatz and Kenney, 2007b), and separated by at 
least 4.0 cm to ensure no cross-reactivity of pharmacological agents being delivered. Initial 
insertion trauma was allowed to subside for 60–120 minutes, during which time lactated 
Ringer solution was perfused through all fibers at a rate of 2 µL/min (Bioanylitical Systems 
Bee hive and Baby Bee microinfusion pumps, West Lafayette, IN). 
 
Skin blood flow was measured using laser-Doppler flowmetry probes (MoorLAB, Moor 
Instruments, UK) placed over each microdialysis site to provide an index of cutaneous red 
blood cell flux, which was measured continuously during the experiment. Arterial blood 
pressure was measured via brachial auscultation every 5 minutes following hyperemia. 
 
 
 
  
 
Mean arterial pressure (MAP) was calculated as [1/3 systolic blood pressure) + (2/3 diastolic 
blood pressure)]. Skin blood flow was expressed as cutaneous vascular conductance (CVC; 
red blood cell flux/MAP) and expressed as absolute CVC and percent change from baseline 
CVC values (%ΔCVCbase). Local skin temperature (Tskl) was controlled at each site by 
using Peltier elements (Newport Temperature Controller 350B) with a laser Doppler probe 
secured through the center of each device. 
 
Local cooling protocol—Following hyperemia (90–120 minutes), local skin temperature 
was clamped at 34°C and laser Doppler probes were attached over each site. ‘Drug-free’ 
baseline values were recorded for 15 minutes before microdialysis sites were perfused with 
Ringers to serve as control, 5mM yohimbine + 1 mM proprananol (Y + P) to antagonize α- 
and β-adrenoceptors (USP, Rockville, MD), 3 mM fasudil to inhibit Rho-Kinase (Tocris, 
Bioscience, Ellisville, MO), or Y + P + fasudil to simultaneously antagonize adrenoceptors 
and inhibit Rho-Kinase activity at a rate of 2 µL/min for 60 minutes. All pharmacological 
solutions were mixed immediately prior to usage, dissolved in lactated Ringer solution, and 
sterilized using syringe microfilters (Acrodis4c, Pall, Ann Arbor, MI, USA). The efficacy of 
the Rho-Kinase specific antagonism and concentrations of the pharmacological agents used 
in this study have been demonstrated in other studies and using the same intradermal 
microdialysis technique (Fasudil Ki = 0.33 µM) (Lang et al., 2009; Thompson-Torgerson et 
al., 2007b; Thompson and Kenney, 2004; Uehata et al., 1997). 
 
Following 60 minutes of drug perfusion, and 15 minutes of ‘drug perfusion’ baseline data, 1 
µM norepinephrine + 1 mg/ml L-ascorbate (preservative; Sigma-Aldrich, St. Louis, MO) 
(Hughes and Smith, 1978) were perfused through all sites for 4 minutes to test vascular 
responsiveness and the integrity of the of the Y + P adrenoceptor antagonism. Following a 
30 minute washout period to allow CVC to recover to pre-norepinephrine values, all sites 
were cooled at a rate of 3°C/min, and Tskl was clamped at 24°C for 40 minutes. A 
representative tracing illustrating the phases of the local cooling response from a 
normotensive and a hypertensive subjects’ control sites are illustrated in Figure 3. Sites were 
rewarmed to 34°C before local temperature was increased to 39°C and 28 mM sodium 
nitroprusside (SNP) was perfused to induce maximal cutaneous vasodilation (CVCmax) 
(Holowatz and Kenney, 2007c; Minson et al., 2002). This temperature was selected due to 
the large surface are of the peltier devices causing discomfort at higher temperatures, and no 
further increase in SkBF was elicited above 39°C in combination with 28 mM SNP during 
pilot testing. 
 
In Vitro Skin Sample Analysis 
Ventral forearm skin samples were obtained on a separate day from the in vivo functional 
assessment of vasoreactivity and on the opposite arm. Using sterile technique two 3mm 
diameter skin samples were obtained. The skin was anesthetized using 2% lidocaine without 
epinephrine. Samples were rinsed in lactated Ringers and immediately frozen in liquid 
nitrogen and stored at −80°C until analysis. 
 
ROCK activity and expression—ROCK activity was measured in skin biopsy lysates 
using the ROCK Activity Immunoblot Kit (Cat# STA-415, Cell Biolabs). Skin samples were 
 
 
  
 
homogenized in RIPA buffer containing protease and phosphatase inhibitors (Kim et al., 
2009; Smith et al., 2011). Samples were centrifuged at 12,000 rpm for 10 min. Supernatants 
were collected and protein concentrations were determined using the BioRad Protein Assay 
Reagent (BioRad). Equal amounts of protein from each sample (=18 ug) were withdrawn 
from each sample and the volume was made up to 25 ul with RIPA buffer. Kinase reaction 
was initiated by adding 50 ul of kinase buffer containing ATP and recombinant MYPT-1 
substrate, prepared per vendor’s instructions. For some of the samples, a second reaction 
was initiated with the ROCK inhibitor fasudil added at a final concentration of 50 uM. The 
reaction was allowed to proceed at 37 C for 60 min with gentle agitation and terminated by 
the addition of 16 ul of 5× SDS PAGE sample buffer. Samples were then boiled for 5 min 
and centrifuged at 12,000 rpm for 1 min. 35 ul of each sample were resolved by SDS PAGE 
and electro-transferred to nitrocellulose. The membranes were blocked for 1 h at room 
temperature (5% nonfat dry milk, in Tris-buffered saline containing 0.1% Tween-20; 
TBST). After rinsing, the membrane was cut at MW 75kDa and incubated with a primary 
antibody to phospho-MYPT1 Thr696 (bottom half, 1:1000, provided in the kit) or ROCK 
(top half, 1:1000; SantaCruz Biotech). Bound antibody was detected with horseradish 
peroxidase conjugated secondary antibody (1:1000; from kit for pMYPT; BioRad for 
ROCK) and visualized using enhanced chemiluminescence. The pMYPT half was then 
stripped with Restore Plus Western blot Stripping buffer (Thermo), and used to examine 
GAPDH (1:1000, Novus) abundance to normalize protein loading. Densitometry analysis 
was performed using ImageJ software (NIH). 
 
Data and Statistical Analysis 
Data were digitalized at 40 Hz, recorded and stored for offline analysis using Windaq 
software and Dataq data acquisition system (Windaq; Dataq Instruments, Akron, OH). 
Baseline values were determined as the last 5 minutes of each baseline phase. Time course 
local cooling data are presented as mean values over 5 minute intervals throughout the 
duration of the cooling protocol. Early and Late phase data are expressed as mean values for 
1–5 and 35–40 minutes of cooling, respectively. 
 
Student’s unpaired t-tests were used to compare physical characteristics between subject 
groups. CVC data were analyzed using three-way, mixed model, repeated measures 
ANOVA protocol (group * pharmacological site * local cooling VC phase; proc mix SAS 
9.2). Specific planned comparisons were performed when appropriate to determine where 
differences between groups and pharmacological sites occurred with appropriate Bonfferoni 
correction. The level of significance was set at α = 0.05. Values are presented as means ± 
SE. 
 
Results   
The physical characteristics of the subjects are presented in Table 1. Groups were matched 
for anthropometric parameters, lipid profile, and total cholesterol. Pre- to satge 1 
hypertensive subjects showed a significantly higher resting systolic, diastolic (p < 0.01) and 
mean arterial blood pressure (p < 0.001) compared to normotensive age-matched controls. A 
significant positive correlation for LDL cholesterol and MAP was present within the HT 
 
 
  
 
group (r = 0.85, p < 0.05), but ceased to be significant when groups were combined (r = 
0.40, p = 0.08). 
 
Figure 2 shows densitometric analysis and representative Western blots of ROCK 
expression and activity (pMYPT-1) from the skin biopsy samples for both groups. There 
was no difference in ROCK expression between groups. ROCK activity was significantly 
increased in skin samples form the HT group, as evidenced by increased phosphorylation of 
recombinant MYPT-1. Fasudil (50 uM) inhibited ROCK dependent MYPT-1 
phosphorylation in this assay (pMYPT-1 not detected in the presence of Fasudil; data not 
shown). 
 
Figure 3 illustrates representative skin blood flow tracings during local cooling for a 
normotensive (A) and essential hypertensive subject (B) with ROCK and adrenergically- 
mediated vasoconstriction labeled. 
 
Table 2 shows the absolute CVC values prior to pharmacological drug infusion and after 
localized drug infusion when local skin temperature was clamped at 34°C. There were no 
differences at the control site or at the adrenoreceptor antagonized site between groups. In 
both pre- to stage 1 hypertensive and normotensive subjects fasudil caused a significant 
increase in CVC (p<0.0001) but there were no differences between the groups. The 
combination of fasudil and adrenoreceptor antagonism resulted in vasodilation in both 
groups (p<0.0001), and the vasodilation was greater in the hypertensive group (p=0.002). 
Figure 4 illustrates the local cooling response (ΔCVC%baseline) normalized to baseline 3 
(drug baseline) at different pharmacological sites in normotensive (A) and pre- to stage 1 
hypertensive (B) groups. A greater vasoconstriction was observed in the HT group during 
minutes 6–25 of local cooling with ROCK and adrenoceptor antagonism. When data are 
normalized as a percentage of change from baseline after perfusion of site specific 
pharmacological agents, with exception of a greater vasoconstriction in the HT group at 5–9 
minutes of local cooling at the control site (HT: −57±5 versus NT: −45±12 ΔCVC 
%baseline 3; p=0.003), no further differences were observed between groups at control, 
ROCK-inhibited, or adrenoceptor antagonized sites. 
 
Figure 5 shows absolute cutaneous vascular conductance (flux/MAP) calculated ROCK- 
dependent (control – fasudil site) and adrenergically-mediated (control – Y + P site) 
vasoconstriction in both groups during early (1–5 min) and late (36–40 min) phases of local 
cooling (ΔCVCbaseline). In absolute terms during early phase local cooling pre- to stage 1 
hypertensive subjects showed greater ROCK-dependent (HT: −0.8±0.2 versus NT: −0.3±0.2 
ΔCVCbaseline; P<0.0001) and adrenergic vasoconstriction (HT: −0.2±0.1 versus NT: 
0.04±0.10 ΔCVCbaseline; P<0.0001). During late phase local cooling the HT group continued 
to display greater ROCK-dependent (HT: −0.9±0.1 versus NT: −0.5±0.2 ΔCVCbaseline; 
P<0.0001) and adrenergic vasoconstriction (HT: −0.2±0.1 versus NT: 0.1±0.1 ΔCVCbaseline; 
P<0.0001) compared to normotensives. 
 
Finally, there was no effect of localized microdialysis treatment within each group, however, 
absolute maximal CVC was attenuated in the pre- to stage 1 hypertensive group (HT: 
1.46±0.21 versus NT: 1.78±0.19 CVC, p=0.025). 
 
 
  
 
Discussion 
The major new findings of the present study were that 1) ROCK activity but not ROCK 
expression was increased in pre- to stage 1 essential hypertensive compared to age-matched 
normotensive skin, 2) at thermoneutral baseline the combination of ROCK and 
adrenoreceptor antagonism results in greater vasodilation in the pre- to stage 1 hypertensive 
compared to the normotensive group, and 3) absolute ROCK and adrenergic-dependent 
vasoconstriction were greater during early and late phases of local cooling in the pre- to 
stage 1 hypertensive compared to normotensive group. Together these in vitro molecular and 
in vivo functional findings are the first to suggest that upregulation of ROCK-dependent 
mechanisms contributes to cutaneous microvascular dysfunction in pre- to stage I essential 
hypertensive humans. Further these data suggest that there is an interaction between the 
ROCK and adrenergic pathways contributing to basal vasomotor tone in the cutaneous 
vasculature of humans with pre- and early stage essential hypertension. 
 
In vitro analysis of the skin biopsies showed that pMYPT/ROCK, a surrogate for ROCK 
activity, was increased in samples obtained from the hypertensive compared to 
normotensive subjects; however, ROCK expression did not differ between groups. This 
finding supports the functional in vivo data of augmented ROCK-dependent vasoconstriction 
during early and late phases of local cooling in the pre- to stage 1 hypertensive compared to 
normotensive subjects. Taken together, these data suggest that locally-mediated cutaneous 
vasoconstriction becomes increasingly ROCK-dependent in essential hypertensive skin, 
likely resulting from a post-translational modification upregulating ROCK activity. The 
early stage of disease progression in these subjects may explain the increase in ROCK 
activity but not expression, with animal and in vitro data supporting upregulation of ROCK 
activity by inflammatory stimuli in pathophysiological states, including superoxide anion, 
endothelin-1, (Anggrahini et al., 2009), thromboxane and angiotension II (Seko et al., 2003). 
Furthermore, the mutual inhibition of NO-dependent vasodilation and RhoA/ROCK- 
dependent vasoconstriction pathways, contributes to the upregulation of ROCK activity in 
the absence of ROCK expression via post-translation modification (Eto et al., 2001; Ming et 
al., 2002; Takemoto et al., 2002). In vitro animal models have similarly shown an increase 
in RhoA and ROCK activity with no difference in ROCK expression between normotensive 
versus hypertensive (Ang II, salt-sensitive, stroke-prone and renal hypertensive models) rats 
(Seko et al., 2003), suggesting changes in ROCK expression may potentially occur later in 
disease progression. 
 
During thermoneutral baseline measurements when local skin temperature was clamped at 
34°C there were no differences between the groups in absolute CVC (Table 2) at the control 
site or when ROCK or adrenoreceptors were independently antagonized. This is in contrast 
to data from both animal and human conduit vessel studies which show increased basal 
ROCK and adrenergic-dependent VSMC hypercontractility with hypertension (Masumoto et 
al., 2001). Because factors known to stimulate ROCK include reactive oxygen species 
(ROS) and a number of inflammatory stimuli, the early stage of disease progression in our 
subjects may explain the similarity in cutaneous basal tone observed between groups, and 
the lack of a difference in baseline vasomotor tone after independent fasudil or 
adrenoreceptor antagonism. However, with dual ROCK and adrenoreceptor antagonism the 
 
  
 
hypertensive group vasodilated significantly more than the normotensive group. These data 
suggest that at this pre- to early stage of hypertension there is an interaction between 
adrenoreceptors and ROCK contributing to basal vascular tone. 
 
During our physiological stimulus to induce adrenergic and ROCK-dependent 
vasoconstriction both early and late phase ROCK and adrenergically-mediated VC were 
augmented in the pre- to stage 1 hypertensive compared to normotensive group. These data 
support the present in vitro evidence of increased ROCK activity in the hypertensive 
subjects and are in agreement with animal models which identify the involvement of 
augmented ROCK activity in hypertension (Mukai et al., 2001). Work from our laboratory 
has previously demonstrated no difference in the pattern or magnitude of local cold-induced 
VC in aged compared to young skin, however, there was a shift in the underlying 
mechanisms towards a greater reliance on ROCK-dependent pathways (Thompson- 
Torgerson et al., 2007b). This compensatory mechanism acts to maintain the magnitude of 
VC with aging due to the well characterized attenuation of adrenergically-mediated 
mechanisms resulting from receptor desensitization (Thompson et al., 2005). In contrast to 
what is observed in primary aged skin, both ROCK and adrenergic VC are upregulated in 
pre- to stage I hypertensives compared to age-matched normotensive subjects in the present 
study. The current cooling and baseline data also suggest an interaction between the two 
pathways via ROCK-mediated α2c-adrenoceptor translocation increasing the receptor 
availability on the VSMC surface for norepinephrine binding. 
 
In the present study we examined adrenergic and ROCK-dependent mechanisms in response 
to local cooling. ROCK and endothelium-dependent mechanisms, specifically eNOS, are 
mutually inhibitory (Takemoto et al., 2002). In a similar cohort of human subjects we have 
recently demonstrated that essential hypertensives display an attenuated eNOS-dependent 
vasodilation to local heating. In combination with in vitro analysis of skin biopsies, we 
showed that iNOS-dependent mechanisms were upregulated and limited eNOS-dependent 
vasodilation. One potential mechanism underlying these observations is through an iNOS- 
mediated upregulation of arginase activity thereby limiting NO synthesis through eNOS 
(Smith et al., 2011). In animal models and cell culture, ROCK increases arginase activity, 
inhibiting eNOS gene expression, eNOS activation, and induces NOS uncoupling resulting 
in further superoxide production (Takemoto et al., 2002). Taken together the human and 
animal data strongly suggest that ROCK-dependent mechanisms downregulate the eNOS 
pathway and contribute to endothelial/microvascular dysfunction in essential hypertension. 
 
In the present study we examined a potential mechanism underlying microvascular function 
using the cutaneous circulation as our model. Using physiologically relevant stimuli our 
results are consistent with findings from other circulations (Masumoto et al., 2001) and 
demonstrate a globalized vascular dysfunction. In essential hypertensive vascular pathology 
changes indicative of end organ damage in the cutaneous circulation occur in parallel with 
those in the renal vascular bed (Coulon et al., 2011). In the present study, while the 
magnitude of absolute basal and local cold-induced vasoconstriction were similar between 
groups, in vitro molecular data clearly showed increased ROCK activity. With more 
advanced stages of vascular pathology ROCK expression is increased via inflammatory 
stimuli including angiotensin II, IL-1β, and remnant lipoproteins (Hiroki et al., 2004; Oi et 
 
  
 
al., 2004). These inflammatory pathways and their involvement with augmented ROCK 
activity have yet to be explored in essential hypertensive humans. 
 
Finally, in this cohort of pre-to stage I hypertensives we did find a significant difference in 
absolute maximal cutaneous vascular conductance. We and others have demonstrated this 
using similar techniques in unmedicated essential hypertensive humans (Holowatz and 
Kenney, 2007a; Holowatz and Kenney, 2007c). A reduction of maximal cutaneous vascular 
conductance has been suggested to be the most appropriate way to assess the degree of 
inward vessel remodeling suggestive of more significant and long term microvascular 
dysfunction. In the present study, maximal cutaneous vascular conductance was reduced, 
indicating that vascular smooth muscle cell remodeling has occurred despite the relatively 
young age and pre- to stage I hypertensive status of our cohort. Moreover, these data support 
the notion of the disease progression with a relative endothelial dysfunction occurring in 
parallel with vascular smooth muscle hypertrophy and inward vessel remodeling. 
 
Limitations  
 
Fasudil is the only ROCK inhibitor currently available for use in humans. Fasudil causes 
considerable vasodilation upon administration raising the need for data normalization and 
careful interpretation of the data. Because of the significant vasodilation in response to 
fasudil when data are presented as a relative change from baseline there were no differences 
between the groups. However, as a change in absolute CVC there were differences between 
the groups for both adrenergic and ROCK-dependent vasoconstriction. In the present study a 
‘drug free’ baseline was obtained prior to establishing a secondary drug perfusion baseline. 
Cutaneous vasodilation to fasudil in both groups was considered and data are presented in 
accordance with the results of the in vitro molecular data. 
 
Conclusions 
Hypertension-associated vascular dysfunction is a complex, multifaceted condition which 
occurs simultaneously in multiple vascular beds. Augmented ROCK activity and ROCK- 
mediated vasoconstriction in the cutaneous circulation may precede alterations in conduit 
vessels, making the skin an easily accessible, generalizable vascular bed for assessing in 
vivo vascular function and dysfunction in pre-clinical and cardiovascular disease groups 
(Abularrage et al., 2005; Holowatz et al., 2008; Rossi et al., 2006; Stewart et al., 2004). The 
present data are the first to indicate a role for ROCK in cutaneous microvascular dysfunction 
in pre- to stage 1 essential hypertension. Because the magnitude of VC to local cooling did 
not differ between groups, coupled with a greater ROCK activity, and attenuated NO- 
dependent vasodilation reported form our previous studies, detectable endothelial 
dysfunction may either precede or occur simultaneously with VSMC dysfunction in the 
disease progression of essential hypertension. Alterations in ROCK expression and an 
increase in the magnitude of locally-mediated VC may occur later in the disease 
progression. Considering the pre- to stage 1 hypertensive status of the present subjects, these 
data are important in understanding early disease progression (Jablonski et al., 2012), in 
which early changes in the ROCK signaling pathway occurs in advance of decrements in 
vascular function. The higher cardiovascular disease risk associated with ‘pre-hypertension’ 
 
 
  
 
(120–129 mmHg), makes this particularly important for early detection and identifying 
preventative strategies (Kokubo et al., 2008; Mancia, 2007; Vasan et al., 2001). 
 
In summary, ROCK activity was increased in skin samples from pre- to stage I essential 
hypertensive humans. Moreover both ROCK and adrenergically-mediated vasoconstriction 
were upregulated in the hypertensive group. Taken together these findings suggest that 
ROCK contributes to cutaneous microvascular dysfunction in essential hypertensive humans 
and may be a potential molecular target in the treatment of hypertension. 
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Highlights 
• ROCK and adrenergically-mediated VC were examined in hypertensive human 
cutaneous circulation. 
• ROCK and adrenergic VC were upregulated in HT vs. NT despite a similar 
magnitude of VC. 
• ROCK activity but not expression was increased in skin samples from 
hypertensives. 
• ROCK contributes to cutaneous microvascular dysfunction in early stage 
essential hypertension. 
  
 
 
 
Figure 1. 
Schematic of the local cooling protocol. Drug-free baseline (BL1), drug baseline (BL2), post 
norepinephrine (NE) baseline (BL3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2. 
Rho-Kinase (ROCK) and pMYPT-1. ROCK expression and activity (MYPT-1 
phosphorylation) were determined by Western blotting. Sample blots are shown in top left 
panel. Densitometry analysis was performed using ImageJ software (NIH). * p<0.05, ** 
P<0.01 difference from the normotensive group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3. 
Representative skin blood flow tracings during local cooling for a normotensive (A) and 
essential hypertensive (B) subject. Adrenergic and ROCK-mediated vasoconstriction are 
labeled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 
Cutaneous vascular conductance (ΔCVC %baseline 3)- in (A) normotensive controls and (B) 
essential hypertensive subjects at baseline (BL; during drug perfusion), and during a local 
cooling protocol to 24°C at the control site, ROCK inhibited, adrenoceptor inhibited, and 
ROCK + adrenoceptor inhibited. Values significantly different from normotensive group: 
Control site ** p<0.001; ROCK + Adrenergic Inhibited site † p<0.05, †† p<0.01, ††† 
p<0.001. 
 
 
 
 
 
Figure 5. 
Cutaneous vascular conductance (ΔBL1) in normotensive controls and essential hypertensive 
subjects for ROCK-mediated (control – fasudil site) and adrenergically-mediated (control – 
Y + P site) vasoconstriction during (A) early phase local cooling (1–5 minutes), and (B) late 
phase local cooling (35–40 minutes) Values significantly different from normotensive 
group: *** p<0.001. 
 
 
 
 
 
Table 1 
Participant characteristics (mean ± SE). Blood pressure values represent a mean of the initial 5 readings during 
the experiment. 
 
 Normotensive Pre/ stage 1 Hypertensive 
Subjects (male, female) (3, 8) (5, 4) 
Age (years) 51 ± 1 50 ± 1 
BMI 25 ± 0 27 ± 0 
Systolic BP (mmHg) 114 ± 1 136 ± 1** 
Diastolic BP (mmHg) 72 ± 1 88 ± 1** 
MAP (mmHg) 86 ± 1 106 ± 3*** 
Glucose (mg·dL−1) 91 ± 1 96 ± 1 
HDL (mg·dL−1) 52 ± 1 57 ± 2 
LDL (mg·dL−1) 108 ± 2 112 ± 2 
** 
P<0.01, 
*** 
P<0.001 difference from the normotensive age match control group. 
 
 
 
 
 
Table 2 
Cutaneous vascular conductance (CVC) at all microdialysis sites after 40 minutes of perfusion with site 
specific antagonists when local temperature was clamped at 34°C in normotensive and hypertensive subjects. 
 
Baseline (CVC) 
Site NT HT  
Control 0.43 ± 0.07 0.36 ± 0.07  
ROCK-inhibited 1.11 ± 0.17† 1.09 ± 0.21†  
Adrenoceptor-inhibited 0.47 ± 0.07 0.40 ± 0.05  
ROCK + Adrenoceptor-inhibited 0.99 ± 0.12† 1.31 ± 0.23†*  
* 
p=0.002 versus the normotensive ROCK + Adrenoreceptor-inhibited site 
† 
p<0.0001 versus the control site 
